

4 November 2025

Migraine Treatments

A. How many patients have been treated with the following drugs in the past 4 months: (June to September figures below)

- **Atogepant (Aquipta) – any disease** – 26 patients
- **Erenumab (Aimovig) - any disease** - treatment available within department, but no patients have commenced on it as of yet.
- **Eptinezumab (Vypti) – any disease** - treatment available within department, but no patients have commenced on it as of yet.
- **Fremanezumab (Ajovy) - any disease** - treatment available within department, but no patients have commenced on it as of yet.
- **Galcanezumab (Emgality) - any disease** - 18 new patients commenced treatment. This number does not take into account the review patients
- **Rimegepant (Vydura) – any disease** - 9 patients
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY** - 101 patients

B. How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)** - 7 patients

C. Are you required to complete Blueteq for the following product classes:

No – Blueteq is not required

- **Botulinum Toxin (Botox, Dysport, Xeomin)**
- **Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab)**
- **Gepants (e.g. rimegepant, atogepant)**